These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 11236026)

  • 1. Ongoing and planned trials of hormonal therapy and trastuzumab.
    Nicholson BP
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):33-7; discussion 92-100. PubMed ID: 11236026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ongoing and planned adjuvant trials with trastuzumab.
    Perez EA; Hortobagyi GN
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):26-32; discussion 92-100. PubMed ID: 11236024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of HER-2 expression in predicting response to therapy in breast cancer.
    Mass R
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):46-52; discussion 92-100. PubMed ID: 11236028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
    Fornier M; Esteva FJ; Seidman AD
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):38-45; discussion 92-100. PubMed ID: 11236027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2/neu expression in primary and metastatic breast cancer.
    Lower EE; Glass E; Blau R; Harman S
    Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and planned clinical trials with trastuzumab (Herceptin).
    Baselga J
    Semin Oncol; 2000 Oct; 27(5 Suppl 9):27-32. PubMed ID: 11049054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.
    Agus DB; Bunn PA; Franklin W; Garcia M; Ozols RF
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100. PubMed ID: 11236029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.
    Pegram MD; Slamon DJ
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):89-95. PubMed ID: 10482199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer.
    Leonard DS; Hill AD; Kelly L; Dijkstra B; McDermott E; O'Higgins NJ
    Br J Surg; 2002 Mar; 89(3):262-71. PubMed ID: 11872048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
    Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway.
    Witters L; Engle L; Lipton A
    Oncol Rep; 2002; 9(6):1163-6. PubMed ID: 12375012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab and chemotherapeutics: drug interactions and synergies.
    Pegram MD; Lopez A; Konecny G; Slamon DJ
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):21-5; discussion 92-100. PubMed ID: 11236023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of Herceptin combined with Taxol on patients with Her-2/neu overexpressing metastatic breast cancer].
    Luo RC; Li AM; Zhang JY; Liao WJ; Ji CY; Miao JX
    Zhonghua Zhong Liu Za Zhi; 2004 Jan; 26(1):52-4. PubMed ID: 15059359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.